Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lot-to-lot consistency of Ad26.ZEBOV and MVA-BN-Filo vaccine regimen
NCT04228783Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2020
- Primary completion
- Apr 2022
- Modality
- Viral Vector Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of zabdeno and Mvabea in Ebola virus disease (EVD) (6 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Geometric Mean Concentrations of Binding Antibody Levels Against the Ebola Virus Glycoprotein. Started Feb 2020; status: completed.
02
Drugs
zabdenoMvabea
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT04228783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04228783.